Navigation Links
MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/14/2008

by MiddleBrook's common stockholders, and other customary closing conditions, and assuming stockholder approval is obtained, is expected to close promptly following the special meeting of stockholders scheduled for September 4, 2008.

Keflex(R) Capsules (Cephalexin, USP) - Commercialization Update

During the second quarter, MiddleBrook continued the commercialization of its 750 mg strength Keflex capsules through a targeted and dedicated national contract sales force. Based on prescription data from IMS Health, total prescriptions filled for Keflex 750 mg capsules in the second quarter of 2008 were 66,811 prescriptions, compared to first quarter 2008 prescriptions of 68,064.

MiddleBrook is currently marketing Keflex 750 mg capsules through its sales force of approximately 30 contract sales representatives and three MiddleBrook district sales managers.

MOXATAG(TM) (amoxicillin extended-release) Tablets

On January 23, 2008, MiddleBrook received U.S. Food and Drug Administration (FDA) approval of the Company's New Drug Application (NDA) for its once-daily amoxicillin PULSYS(R) product, under the trade name, MOXATAG(TM) (amoxicillin extended-release) Tablets. MOXATAG is approved for the treatment of pharyngitis and/or tonsillitis secondary to Streptococcus pyogenes (strep throat) in adults and pediatric patients 12 years or older.

During the second quarter, MiddleBrook was actively engaged in the commercial manufacture, testing and validation of its MOXATAG scaled-up tablet production process in cooperation with its contract manufacturer, STADA Production in Clonmel, Ireland. The Company believes it will be prepared for a potential commercial launch of MOXATAG during the first half of 2009, assuming the closing of the EGI transaction in September 2008.

MOXATAG is the first and only once-daily aminopenicillin therapy approved by the FDA to treat strep throat. Physicians prescribing MOXATAG would be able to provide their pat
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
2. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
5. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
6. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
7. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
8. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
9. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
10. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
11. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to announce a ... Q-Suite is their flagship contact center ACD system for Asterisk-based call centers . ... shows the script components to the agent only when wanted, and allows for validation ...
(Date:7/31/2015)... Minneapolis, Minn. (PRWEB) , ... July 31, 2015 ... ... software, is selected as a contributor for LeadingAge’s Center for Aging Services Technologies ... studies designed to help long-term and post-acute care providers understand the benefits of ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
(Date:7/31/2015)... OR (PRWEB) , ... July 31, 2015 , ... New ... Granary District Stage Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. ... an exciting and important day for the entire community as the culmination of months ...
(Date:7/31/2015)... ... July 31, 2015 , ... An ... from NBC talked about a woman’s unfortunate experience having cosmetic skin procedures done ... face, which resulted in blistering, swelling, bruising, and pain. This woman’s experience is ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3
... 2012)When combined with other treatments, the drug cetuximabwhich works ... been shown to extend survival in certain types of ... percent of colorectal cancer patientsspecifically those who carry a ... to the drug. Researchers at Fox Chase Cancer ...
... the next generation of global health scientists, Fogarty International ... Health are building a network of U.S. academic institutions ... a significant mentored research experience in a developing country. ... over the next five years to support 400 early-career ...
... autoimmune diseases also display a tendency to develop atherosclerosis ... arteries. Clinical researchers at LMU, in collaboration with colleagues ... to explain the connection between the two types of ... of immune cells called plasmacytoid dendritic cells (pDCs). pDCs ...
... ,People with metal-on-metal hip replacements do not have an increased ... receive the device, according to a new study. However, ... Universities of Bristol and Exeter in the U.K. report. ... and Wales, which contains records on more than 1 million ...
... News) -- A new study finds that preteen girls ... experience side effects after receiving the human papillomavirus (HPV) vaccine, ... are similar to those associated with other vaccines. U.S. ... to 26, within two weeks after they received the Gardasil ...
... April 3 (HealthDay News) -- Adding the drug cetuximab (brand ... colon cancer did not improve disease-free survival in patients, a ... who undergo surgery have a 50 percent chance of cure, ... leucovorin, fluorouracil and oxaliplatin (a regimen known as FOLFOX) after ...
Cached Medicine News:Health News:Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 3Health News:The long arm of the dendritic cell 2Health News:The long arm of the dendritic cell 3Health News:No Added Cancer Risk From Hip Replacement Materials: Study 2Health News:Preteens More Likely to Report HPV Vaccine Side Effects 2Health News:Experimental Chemo Combo for Colon Cancer Disappoints 2
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: ... Cytometer, a flexible, reliable and scalable system that can analyze ... research applications.   “We engineered cutting-edge innovation ... three foundations in mind,” said James Glasscock, President of Cell ...
... 2011 Ann Arbor SPARK recently celebrated the conclusion of ... a reception.  At the Ann Arbor SPARK Boot Camp Celebration, ... Camp" winner, based on the quality of its investor pitch ... though the Ann Arbor SPARK Business Accelerator.   ...
Cached Medicine Technology:BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 2BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 3Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2
... tasks and delivers consistently reliable ... and ensure testing accuracy in ... automated reticulocyte counts and three-dimensional ... sensitivity, specificity and efficiency in ...
... staff scheduling solution that streamlines and ... the synchronization and interface of workforce ... maintains staff schedules and replacements; tracks ... shift and work location schedules; and ...
... A first of its kind product, ... most appealing colors and state-of-the-art SPECT technology ... cardiology system. The exclusive, contoured patient chair ... cardiac scanning. A relaxed patient moves ...
... Series of Cryoablation Catheters combines the safeguard ... the two-stage cooling system of the CryoCor ... of cryoenergy to the ablation site. CryoCor's ... create the transmural lesions necessary to permanently ...
Medicine Products: